- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05415904
Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools (HANTA-NE)
Hantaviruses are emerging pathogens responsible for hemorrhagic fever with renal syndrome. Severity risks factors aren't consensual in litterature, mostly related to scandinavian cohorts. A prognostic score was created to help patient's orientation in healthcare system but wasn't independantly validated (Hentzien, Emerging infectious diseases 2018).
This retrospective cohort of hantavirus infected hospitalized adults patients in the north-eastern quarter of France between 2013 and 2022 will specify the kidney damage during infection and risk factors for a severe form (defined par acute kidney injury KDIGO 3). The previous prognostic score performance will be evaluated in this cohort.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
-
Nancy, Frankrig, 54000
- Central Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- hantavirus proven by serology infection
- age above 18 years
- Hospitalisation
Exclusion Criteria:
- age under 18 years
- fulfill opposition form
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kohorte
- Tidsperspektiver: Tilbagevirkende kraft
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
HANTA-NE
All adult patient hospitalized for hantavirus infection between 01/01/2013 and 31/12/2022 in North Eastern France
|
Observational cohort study
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Creatinin level
Tidsramme: Through study completion, an average of 2 years
|
Acute Kidney injury KDIGO 3
|
Through study completion, an average of 2 years
|
Hemorrhagic syndrome
Tidsramme: Through study completion, an average of 2 years
|
Major bleeding requiring blood transfusion
|
Through study completion, an average of 2 years
|
Death
Tidsramme: Through study completion, an average of 2 years
|
Death
|
Through study completion, an average of 2 years
|
Hospitalisation in intensive care unit
Tidsramme: Through study completion, an average of 2 years
|
Hospitalisation in intensive care unit
|
Through study completion, an average of 2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Score performance to predict severity
Tidsramme: Through study completion, an average of 2 years
|
Correlation between severity predicted by the score and bio-clinical severity during hospitalization. Score composition : Hematuria = 7 Visual disorders = 8 Leucocyte count > 10 x 10^9 cells/L = 9 Nephrotoxic drug exposure (NSAID, iodinated contrast media, diuretics, renin angiotensin aldosterone system inhibitors, aminoglycosides, glycopeptides) = 10 Thrombocytopenia < or = 90 000/mm3 = 11 Risk group according score scale 0-10 Low risk 11-19 intermediate risk 20-45 high risk |
Through study completion, an average of 2 years
|
Hypotension
Tidsramme: Through study completion, an average of 2 years
|
Lowest systolic blood presure during hospitalisation < 90mmHg
|
Through study completion, an average of 2 years
|
Proteinuria
Tidsramme: Through study completion,an average of 2 years
|
Proteinuria during hospitalisation defined by proteinuria/creatininuria above 500 mg/g or equivalent
|
Through study completion,an average of 2 years
|
Urinary dipstick
Tidsramme: Through study completion, an average of 2 years
|
Leucocyturia or hematuria
|
Through study completion, an average of 2 years
|
ALAT, ASAT
Tidsramme: Through study completion, an average of 2 years
|
Liver cytolysis
|
Through study completion, an average of 2 years
|
calcium
Tidsramme: Through study completion, an average of 2 years
|
hypocalcemia, hypercalcemia
|
Through study completion, an average of 2 years
|
phosphorus
Tidsramme: Through study completion, an average of 2 years
|
hypophaspahtaemia, hyperphasphatemia
|
Through study completion, an average of 2 years
|
potassium
Tidsramme: Through study completion, an average of 2 years
|
hypokaliemia, hyperkaliemia
|
Through study completion, an average of 2 years
|
sodium
Tidsramme: Through study completion, an average of 2 years
|
blood sodium level disorders
|
Through study completion, an average of 2 years
|
bicarbonate blood level
Tidsramme: Through study completion, an average of 2 years
|
metabolic acidosis, metabolic alcalosis
|
Through study completion, an average of 2 years
|
Heamoglobin
Tidsramme: Through study completion, an average of 2 years
|
Anemia
|
Through study completion, an average of 2 years
|
platelets level
Tidsramme: Through study completion, an average of 2 years
|
thrombocytemia
|
Through study completion, an average of 2 years
|
Urine output
Tidsramme: Through study completion, an average of 2 years
|
Polyruria above 3 L/day
|
Through study completion, an average of 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Alice CORBEL, M.D., Central Hospital, Nancy, France
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2022PI034
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hantavirus Nephropathy
-
National Institute of Allergy and Infectious Diseases...AfsluttetImmunisering | Hantavirus lungeinfektionForenede Stater
-
National Institute of Allergy and Infectious Diseases...AfsluttetHantavirus lungesyndromForenede Stater
-
University of New MexicoNational Institute of Allergy and Infectious Diseases (NIAID)Afsluttet
-
University of New MexicoNational Institute of Allergy and Infectious Diseases (NIAID)AfsluttetHantavirus infektionerChile
-
University of CologneRekrutteringHantavirus infektioner | Hæmoragisk feber med nyresyndrom | Nephropathia Epidemica | Hantavirus Cardiopulmonary SyndromeTyskland
-
U.S. Army Medical Research and Development CommandAktiv, ikke rekrutterende
-
First Affiliated Hospital Xi'an Jiaotong UniversityRekrutteringHæmoragisk feber med nyresyndromKina
-
U.S. Army Medical Research and Development CommandTrukket tilbageHæmoragisk feber med nyresyndromTyskland
-
U.S. Army Medical Research and Development CommandWalter Reed Army Institute of Research (WRAIR); US Army Medical Research... og andre samarbejdspartnereAfsluttetHæmoragisk feber med nyresyndromForenede Stater
-
U.S. Army Medical Research and Development CommandTilmelding efter invitation
Kliniske forsøg med HANTA-NE
-
SEAMEO Regional Centre for Food and NutritionIndonesia University; Ministry of Health Republic of Indonesia; Health Polytechnic... og andre samarbejdspartnereUkendtAnæmi | Stunting | Supplerende fodringsanbefaling | Lineær programmering | Indonesien | Spædbørn og småbørn | Problem med næringsstofferIndonesien
-
University of ValenciaHospital de la RiberaUkendt
-
Medline IndustriesF2 LabsIkke rekrutterer endnuVedhæftning af den neutrale elektrode 21pad
-
TakedaEA Pharma Co., Ltd.AfsluttetInvolutionær osteoporoseJapan
-
GlaxoSmithKlineTrukket tilbage
-
University of VermontAfsluttet
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Afsluttet
-
University of MemphisNational Institute on Alcohol Abuse and Alcoholism (NIAAA)AfsluttetDruk | Alkoholdrikning på college | Adfærd og adfærdsmekanismer | Opførsel, drikkeForenede Stater
-
University of NottinghamUkendt
-
Shanghai Mental Health CenterRekrutteringSkizofreni | Transkranielle vekselstrømsstimuleringer | Negative symptomerKina